Flu Vaccine Is a Hard Sell to Some Parents of Children With Asthma

BY SUSAN LONDON
Contributing Writer

Seattle — In one-third of children with asthma who are not vaccinated against influenza, the vaccine is withheld because parents believe it has no benefit, according to results of a study of 93 children and their parents.

Influenza exacerbates asthma, and annual flu vaccination is recommended for high-risk children, including those with chronic asthma, Dr. Sudha Reddy, a fellow at the Children’s Hospital of Michigan in Detroit, and her colleagues reported at the annual meeting of the American College of Allergy, Asthma, and Immunology.

To determine the prevalence of flu vaccination among children with asthma and reasons for receipt and nonreceipt of the vaccine, the investigators conducted a clinic-based study in the fall of 2004.

“During that year, there was a nationwide shortage of flu vaccine due to manufacturing problems,” Dr. Reddy noted in an interview. Given media coverage of the shortage and the resulting increased public awareness, Dr. Reddy and her colleagues hypothesized that vaccination rates would be high.

Study participants were aged 5-18 years, had established asthma, and were visiting an allergy clinic in a university-affiliated hospital. They and their parents completed questionnaires asking about demographics, the severity of their asthma, their influenza vaccination status, and reasons for vaccinating or not vaccinating.

Asthma was rated as mild in 55% and as moderate or severe in 45%. Sixty-seven percent of the children received the flu vaccine. The leading reason parents gave for having their children vaccinated was a recommendation by a physician.

The leading reason parents gave for not vaccinating was that a physician recommended it (44%). Other reasons included: waiting to get the vaccine on an annual basis (21%), hearing about it through school (15%), being aware of the vaccine (12%), and news of the vaccine shortage (8%).

On the other hand, the leading reason parents gave for vaccinating their children was lack of benefit of the vaccine, cited by 32%, which Dr. Reddy commented was surprising. Other reasons included a previous experience of vaccine-related adverse events (22%), a perception that the children would not get the flu (16%), a preference that the children would become ill rather than receive the vaccine (10%), an allergy to eggs (6%), a preference not to vaccinate (6%), and failure of the physician to recommend vaccination (3%).

In terms of perceived benefits of the flu vaccine, 48% of parents overall believed that it prevented influenza illness, and 47% believed that it helped control asthma. Among children who received the vaccine, the most common adverse events were local pain (44%) and fever (13%). Only 2% experienced a worsening of their asthma.

The majority of parents (61%) said that their physician was their source of information about flu vaccination. Other sources included the media (23%), news regard the vaccine shortage specifically (13%), and family members (3%).

The investigators concluded that physicians remain the best source of information on the flu vaccine for most patients and should discuss the topic with patients at every opportunity for vaccination. Dr. Reddy reported that she had no conflicts of interest in association with the study.

Steroid Nasal Spray Fails to Foil OME In Young Children

RIO GRANDE, PUERTO RICO — Intransal corticosteroids were no better than placebo for curing otitis media in children aged 4-11 years, based on data from a study of more than 200 children.

Dr. Ian Williamson of the University of Southampton (England) and his colleagues hypothesized that off-label intranasal corticosteroids might be effective against otitis media with effusion (OME), which is among the most common indications for surgery in young children in the United Kingdom.

The investigators randomized 217 children with OME diagnoses to receive 50 mcg of mometasone spray or a placebo spray in each nostril once daily for 3 months. The children were referred for the study from 99 family practices in the United Kingdom between 2004 and 2007.

The primary outcome was resolution of infection in at least one ear after 1 month, based on tympanometry data. Overall, the cure rate at 1 month was 41% among the 105 children who received corticosteroids and 45% among the 112 children who received the placebo spray. A secondary analysis at 3 months showed similar results, with cure rates of approximately 50% in each group, Dr. Williamson said at the annual meeting of the North American Primary Care Research Group.

Adverse events included nasal stinging, dry throat, cough, and nosebleed, but the incidence of these events was not significantly different. Dr. Williamson stated that he had no financial conflicts to disclose.

By Heidi Splete